Skip to main content
. Author manuscript; available in PMC: 2015 Jun 9.
Published in final edited form as: Dev Cell. 2014 May 29;29(5):521–533. doi: 10.1016/j.devcel.2014.04.027

Figure 7. Fetal Oocyte Attrition and Meiotic Prophase I Progression in AZT-treated Mice.

Figure 7

(A) Diagram of AZT treatment of pregnant WT and Mael+/− mutant females.

(B) Quantification of untreated and AZT-treated WT and Mael-null oocytes. Mean ± St.dev. from at least three independent measurements are shown (two-tailed unpaired Student's t-test, ns-P>0.05; ***-P<0.001; ** - P<0.01, *-P<0.05).

(C) Whole mount TRA98 (green) labeling of fetal oocytes in untreated and AZT-treated WT and Mael-null ovaries.

(D) Dot-plot of RMN L1ORF1p levels in AZT-treated WT and Mael-null oocytes (two-tailed Kolmogorov-Smirnov test, ns-P>0.05, ***-P<0.001).

(E) Quantification of untreated and AZT-treated WT and Mael-null E18.5 oocytes exhibiting evidence of DNA damage and MSUC (by γH2AX staining), persistent DSBs (by RAD51 foci), asynapsis (by abnormal SYCP2 staining), MSUC (by BRCA1 staining) and lacking MLH1 foci. (Two-tailed Fisher's exact test, ns-P>0.05; ***-P<0.001; ** - P<0.01, *-P<0.05).

See also Figures S3 and S5, and Tables S3 and S7.